These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 25072648)

  • 21. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration.
    Yonekawa Y; Andreoli C; Miller JB; Loewenstein JI; Sobrin L; Eliott D; Vavvas DG; Miller JW; Kim IK
    Am J Ophthalmol; 2013 Jul; 156(1):29-35.e2. PubMed ID: 23668679
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.
    Gharbiya M; Cruciani F; Mariotti C; Grandinetti F; Marenco M; Cacace V
    J Ocul Pharmacol Ther; 2015; 31(6):357-62. PubMed ID: 26133059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab.
    Freund KB; Hoang QV; Saroj N; Thompson D
    Ophthalmology; 2015 Sep; 122(9):1802-10. PubMed ID: 26025097
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes.
    Karakurt Y; Ucak T; Taslı G; Agcayazı B; İcel E; Yılmaz H
    Med Sci Monit; 2018 Dec; 24():9019-9025. PubMed ID: 30542050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept.
    Hariri A; Diniz B; Fou LV; Lam LA; Nittala MG; Sadda SR
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):195-200. PubMed ID: 25707044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.
    Rahimy E; Shahlaee A; Khan MA; Ying GS; Maguire JI; Ho AC; Regillo CD; Hsu J
    Am J Ophthalmol; 2016 Apr; 164():118-27.e2. PubMed ID: 26748058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration.
    Messenger WB; Campbell JP; Faridi A; Shippey L; Bailey ST; Lauer AK; Flaxel CJ; Hwang TS
    Br J Ophthalmol; 2014 Sep; 98(9):1205-7. PubMed ID: 24795334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials.
    Bakri SJ; Moshfeghi DM; Francom S; Rundle AC; Reshef DS; Lee PP; Schaeffer C; Rubio RG; Lai P
    Ophthalmology; 2014 May; 121(5):1102-8. PubMed ID: 24393349
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry.
    Atchison EA; Wood KM; Mattox CG; Barry CN; Lum F; MacCumber MW
    Ophthalmology; 2018 May; 125(5):676-682. PubMed ID: 29336897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment.
    Gerding H
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):560-3. PubMed ID: 25902122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration.
    Barthelmes D; Campain A; Nguyen P; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Gillies MC;
    Br J Ophthalmol; 2016 Dec; 100(12):1640-1645. PubMed ID: 26994110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study.
    Kim JH; Lee DW; Chang YS; Kim JW; Kim CG
    Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2101-2109. PubMed ID: 27230919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.